Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 67

1.
2.

A systematic literature review of the efficacy, effectiveness, and safety of filgrastim.

Dale DC, Crawford J, Klippel Z, Reiner M, Osslund T, Fan E, Morrow PK, Allcott K, Lyman GH.

Support Care Cancer. 2018 Jan;26(1):7-20. doi: 10.1007/s00520-017-3854-x. Epub 2017 Sep 22. Review.

PMID:
28939926
3.

Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.

Aapro M, Boccia R, Leonard R, Camps C, Campone M, Choquet S, Danova M, Glaspy J, Hus I, Link H, Sliwa T, Tesch H, Valero V.

Support Care Cancer. 2017 Nov;25(11):3295-3304. doi: 10.1007/s00520-017-3842-1. Epub 2017 Aug 25. Review.

4.

Use of granulocyte-colony stimulating factor to prevent recurrent clozapine-induced neutropenia on drug rechallenge: A systematic review of the literature and clinical recommendations.

Myles N, Myles H, Clark SR, Bird R, Siskind D.

Aust N Z J Psychiatry. 2017 Oct;51(10):980-989. doi: 10.1177/0004867417720516. Epub 2017 Jul 27. Review.

PMID:
28747065
5.

Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related events.

Bond TC, Szabo E, Gabriel S, Klastersky J, Tomey O, Mueller U, Schwartzberg L, Tang B.

J Oncol Pharm Pract. 2017 Jan 1:1078155217714859. doi: 10.1177/1078155217714859. [Epub ahead of print]

PMID:
28614980
6.
7.

The effectiveness and safety of same-day versus next-day administration of long-acting granulocyte colony-stimulating factors for the prophylaxis of chemotherapy-induced neutropenia: a systematic review.

Lyman GH, Allcott K, Garcia J, Stryker S, Li Y, Reiner MT, Weycker D.

Support Care Cancer. 2017 Aug;25(8):2619-2629. doi: 10.1007/s00520-017-3703-y. Epub 2017 May 8. Review.

PMID:
28484882
8.

Pegfilgrastim-Induced Bone Pain: A Review on Incidence, Risk Factors, and Evidence-Based Management.

Moore DC, Pellegrino AE.

Ann Pharmacother. 2017 Sep;51(9):797-803. doi: 10.1177/1060028017706373. Epub 2017 Apr 19. Review.

PMID:
28423916
9.

Over- and under-prophylaxis for chemotherapy-induced (febrile) neutropenia relative to evidence-based guidelines is associated with differences in outcomes: findings from the MONITOR-GCSF study.

Bokemeyer C, Gascón P, Aapro M, Ludwig H, Boccadoro M, Denhaerynck K, Gorray M, Krendyukov A, Abraham I, MacDonald K.

Support Care Cancer. 2017 Jun;25(6):1819-1828. doi: 10.1007/s00520-017-3572-4. Epub 2017 Jan 22.

10.

Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review.

Fernandes R, Mazzarello S, Stober C, Vandermeer L, Dudani S, Ibrahim MF, Majeed H, Perdrizet K, Shorr R, Hutton B, Fergusson D, Clemons M.

Breast Cancer Res Treat. 2017 Jan;161(1):1-10. doi: 10.1007/s10549-016-4028-0. Epub 2016 Oct 25. Review.

PMID:
27783280
11.

Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review.

Younis T, Rayson D, Jovanovic S, Skedgel C.

Breast Cancer Res Treat. 2016 Oct;159(3):425-32. doi: 10.1007/s10549-016-3954-1. Epub 2016 Aug 30. Review.

PMID:
27572552
12.

Mobilization of autologous and allogeneic peripheral blood stem cells for transplantation in haematological malignancies using biosimilar G-CSF.

Schmitt M, Hoffmann JM, Lorenz K, Publicover A, Schmitt A, Nagler A.

Vox Sang. 2016 Aug;111(2):178-86. doi: 10.1111/vox.12397. Epub 2016 Mar 8.

PMID:
27509033
13.

Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor.

Pettengell R, Bias P, Mueller U, Lang N.

Support Care Cancer. 2016 Jun;24(6):2677-84. doi: 10.1007/s00520-015-3057-2. Epub 2016 Jan 16.

PMID:
26780505
14.

Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review.

Mitchell S, Li X, Woods M, Garcia J, Hebard-Massey K, Barron R, Samuel M.

J Oncol Pharm Pract. 2016 Oct;22(5):702-16. doi: 10.1177/1078155215625459. Epub 2016 Jan 13. Review.

PMID:
26769697
15.

Granulocyte-colony stimulating factor for acute-on-chronic liver failure: systematic review and meta-analysis.

Chavez-Tapia NC, Mendiola-Pastrana I, Ornelas-Arroyo VJ, Noreña-Herrera C, Vidaña-Perez D, Delgado-Sanchez G, Uribe M, Barrientos-Gutierrez T.

Ann Hepatol. 2015 Sep-Oct;14(5):631-41. Review.

16.

Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.

Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO; American Society of Clinical Oncology.

J Clin Oncol. 2015 Oct 1;33(28):3199-212. doi: 10.1200/JCO.2015.62.3488. Epub 2015 Jul 13. Review.

PMID:
26169616
17.

The impact of primary prophylaxis with granulocyte colony-stimulating factors on febrile neutropenia during chemotherapy: a systematic review and meta-analysis of randomized controlled trials.

Wang L, Baser O, Kutikova L, Page JH, Barron R.

Support Care Cancer. 2015 Nov;23(11):3131-40. doi: 10.1007/s00520-015-2686-9. Epub 2015 Mar 29. Review.

18.

Pegfilgrastim vs filgrastim in PBSC mobilization for autologous hematopoietic SCT: a systematic review and meta-analysis.

Kim MG, Han N, Lee EK, Kim T.

Bone Marrow Transplant. 2015 Apr;50(4):523-30. doi: 10.1038/bmt.2014.297. Epub 2015 Jan 12. Review.

PMID:
25581410
19.

Economic Evaluation of Primary Prophylaxis Using Filgrastim Versus Pegfilgrastim in Patients With Solid Tumor Cancer: A Systematic Literature Review.

Sun D, Gharaibeh M, Altyar A, MacDonald K, Martin J, Abraham I.

Value Health. 2014 Nov;17(7):A736. doi: 10.1016/j.jval.2014.08.112. Epub 2014 Oct 26. No abstract available.

20.

Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a Center for International Blood and Marrow Transplant Research analysis.

Hsu JW, Wingard JR, Logan BR, Chitphakdithai P, Akpek G, Anderlini P, Artz AS, Bredeson C, Goldstein S, Hale G, Hematti P, Joshi S, Kamble RT, Lazarus HM, O'Donnell PV, Pulsipher MA, Savani BN, Schears RM, Shaw BE, Confer DL.

Biol Blood Marrow Transplant. 2015 Jan;21(1):165-71. doi: 10.1016/j.bbmt.2014.10.007. Epub 2014 Oct 12.

Supplemental Content

Loading ...
Support Center